Bpifrance

Chipiron is a developer of innovative portable MRI machines that utilize advanced quantum detectors to generate three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and efficient, significantly reducing costs compared to traditional MRI technologies. The company's focus on employing quantum sensors enhances the capability of these portable devices for disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions. This approach aims to empower healthcare institutions to improve patient outcomes and decrease the fatality rates associated with neurological diseases.

Fizimed SAS, founded in 2017 and based in Strasbourg, France, specializes in manufacturing a perineal device designed to address urinary incontinence in women through pelvic floor reeducation. The company's flagship product, EMY, is a perineal probe that connects to a mobile app, allowing users to engage in personalized exercises for strengthening pelvic floor muscles. EMY not only captures real-time muscle contractions but also incorporates interactive elements, such as games, to motivate users during their five-minute workouts. Fizimed emphasizes user-friendliness and safety in its product design, aiming to empower women in managing their pelvic health at home. Additionally, the company actively seeks to eliminate the stigma surrounding urinary incontinence, fostering a supportive community on social media where women can share experiences and innovations related to this common health issue. Through its combination of medical efficacy and engaging technology, Fizimed aims to provide women with the tools they need to regain control over their pelvic health in a discreet and enjoyable manner.

SUPERBRANCHE is a biotechnology company focused on the early detection and treatment of metastases using advanced nanotechnology. The company develops therapeutic and diagnostic applications that aim to enhance accessibility and facilitate the timely identification of tumors. Its innovative platform incorporates targeted diagnostic and image-guided therapy nanomaterials, grounded in proprietary technology. This approach enables healthcare providers to detect and address metastases earlier, ultimately improving patient outcomes.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

Okomera is a biotech start-up focused on enhancing the development of precision-based cancer medicines. The company specializes in automating and streamlining individualized tumor biopsy research through innovative medical technologies. By utilizing microfluidic 3D cellular assays, Okomera's approach allows for the prediction of patient-specific responses to therapies. This is achieved by cultivating cells within thousands of microfluidic droplets and exposing them to various conditions in parallel, which accelerates the process of biologically relevant biopsy testing. Consequently, Okomera's technologies enable healthcare providers to expedite cancer treatment, ultimately improving patient outcomes.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

HEPTA Medical is a medical technology company focused on developing a microwave ablation platform for the treatment of early lung cancer. The company's innovative solution includes a microwave ablation catheter equipped with a proprietary temperature sensor, which allows healthcare professionals to monitor and control the ablation volume in real-time. This technology aims to provide a minimally invasive, nonsurgical treatment option, enhancing the efficiency and safety of cancer ablation procedures. By enabling precise control over the size of the lesion being treated, HEPTA Medical seeks to improve patient outcomes in cancer care.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

May Health specializes in developing innovative solutions for infertility related to Polycystic Ovary Syndrome (PCOS). The company offers a minimally invasive procedure aimed at restoring ovulation in women with PCOS, providing a more natural approach to pregnancy. This one-time treatment is performed transvaginally under ultrasound guidance, eliminating the need for general anesthesia. The procedure is designed to assist the body's natural ovulation process and can be conducted in a clinical setting, similar to techniques used by fertility specialists in in vitro fertilization (IVF). May Health's focus is on delivering effective, durable solutions for patients seeking to conceive while minimizing the medicalization of the pregnancy experience.

Pixacare is a company that develops a medical imaging application aimed at enhancing wound care management for healthcare professionals. This secure and collaborative platform automates medical photo management and centralizes essential data for monitoring wounds, making it user-friendly on both mobile and desktop devices. The application is a Class I CE-marked digital medical device that integrates seamlessly with existing healthcare infrastructures, including Patient Administration Systems and Electronic Health Records, ensuring interoperability. By transforming any smartphone camera into a secure documentation tool, Pixacare enables home-care staff, surgeons, and dermatologists to monitor and anticipate complications in chronic and post-surgery wounds. This innovation allows healthcare professionals to optimize their activities and save time in visual specialties while ensuring data security through hosting on certified Health Data Hosting servers.

Chipiron is a developer of innovative portable MRI machines that utilize advanced quantum detectors to generate three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and efficient, significantly reducing costs compared to traditional MRI technologies. The company's focus on employing quantum sensors enhances the capability of these portable devices for disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions. This approach aims to empower healthcare institutions to improve patient outcomes and decrease the fatality rates associated with neurological diseases.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Pixee Medical is a medical technology company based in Chavanod, France, founded in 2017. The company specializes in the manufacturing of computer-assisted surgical solutions that utilize advanced computer vision and artificial intelligence technologies. Pixee Medical produces medical equipment designed to control the positioning of implants during orthopedic surgeries. Its innovative tracking tools enable precise three-dimensional localization of surgical objects, allowing healthcare professionals to perform procedures with millimeter accuracy. By focusing on affordability, Pixee Medical aims to provide effective surgical navigation solutions that address the challenges of the current healthcare environment.

I.Ceram SA is a France-based company that specializes in the design, manufacture, and marketing of alumina bio-ceramic implants for various joints of the human body. Founded in 2005 and headquartered in Limoges, I.Ceram offers a range of implants for the ankle, knee, hip, spine, shoulder, wrist, skull, tibia, and foot, as well as osteosynthesis products. The company operates both domestically and internationally, emphasizing innovation and high-quality materials in its product offerings. I.Ceram is a subsidiary of Investissement Développement.

Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, that specializes in the design, development, and production of amorphous metal parts. Founded in 2017, Vulkam utilizes biocompatible amorphous metal alloys primarily composed of materials such as zirconium, copper, hafnium, nickel, and titanium. The company's innovative products find applications across various industries, including aerospace, automotive, biomedical, cryogenic, watches, jewellery, and micro components. Vulkam's focus on creating micromechanical parts that are significantly smaller yet maintain strength and functionality sets a new standard in metallurgy and metal processing, positioning the company as a leader in the development of advanced metal technologies.

Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, that specializes in the design, development, and production of amorphous metal parts. Founded in 2017, Vulkam utilizes biocompatible amorphous metal alloys primarily composed of materials such as zirconium, copper, hafnium, nickel, and titanium. The company's innovative products find applications across various industries, including aerospace, automotive, biomedical, cryogenic, watches, jewellery, and micro components. Vulkam's focus on creating micromechanical parts that are significantly smaller yet maintain strength and functionality sets a new standard in metallurgy and metal processing, positioning the company as a leader in the development of advanced metal technologies.

Okomera is a biotech start-up focused on enhancing the development of precision-based cancer medicines. The company specializes in automating and streamlining individualized tumor biopsy research through innovative medical technologies. By utilizing microfluidic 3D cellular assays, Okomera's approach allows for the prediction of patient-specific responses to therapies. This is achieved by cultivating cells within thousands of microfluidic droplets and exposing them to various conditions in parallel, which accelerates the process of biologically relevant biopsy testing. Consequently, Okomera's technologies enable healthcare providers to expedite cancer treatment, ultimately improving patient outcomes.

Callyope is a technology company that specializes in remote brain health monitoring. It operates a speech-based platform that uses natural language processing and signal processing techniques to analyze patients' speech, aiding caregivers in detecting relapses and making informed care decisions. This enhances the objectivity and responsiveness of brain health monitoring, potentially improving patients' quality of life and reducing re-hospitalization rates.

Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

Injectpower specializes in developing energy storage technologies and micro-batteries tailored for medical implants. Their core product is a small, solid-state battery that powers implantable devices, enabling them to function as sensors or actuators for extended periods without the need for recharging. With over 16 years of research and 40 patents, Injectpower's batteries are manufactured using a proven semiconductor supply chain, ensuring high reliability. The company's innovative solutions include batteries for devices that monitor intraocular pressure in glaucoma patients and intracranial pressure and fluid flow, allowing physicians to remotely monitor and diagnose conditions more effectively.

Diamidex SAS, established in 2014 and based in Marseille, France, specializes in the development and production of rapid detection tests for legionella, a type of bacteria that can cause severe lung infections. The company offers turnkey test solutions, designed for both laboratory and field use, which provide a semi-quantitative count of microorganisms in water samples and industrial goods. Diamidex's products aim to enhance the accuracy of microbial contamination detection, facilitating quicker experimentation and data collection in research labs.

SFE Process specializes in the design and manufacture of laboratory equipment, particularly focusing on extraction machines that utilize supercritical fluids. The company develops innovative and modular pressure equipment, providing tailored laboratory systems that cater to a variety of applications. By offering flexible and multipurpose extraction systems, SFE Process enables its clients to efficiently achieve their objectives in diverse research and industrial settings.

X-Pressure is a medical device to measure cerebrospinal fluid pressure to better diagnose brain diseases.

SMAIO is a manufacturer of medical devices for spinal pathologies. They provide control over surgical procedures to the spine physician through a range of solutions.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

Hemerion is a biotechnology company dedicated to developing innovative cancer treatments, specifically targeting glioblastoma, the most prevalent and aggressive primary brain tumor. The company operates a platform that integrates therapeutic services at the intersection of surgery and photonics, utilizing a photosensitizing drug for a drug-device combination therapy. This approach enables healthcare professionals to selectively destroy cancer cells in regions that are difficult to access through traditional surgical methods, all while preserving healthy tissues. Hemerion's focus on advanced treatment options aims to enhance the healthcare industry's ability to combat brain cancer and improve patient outcomes in the fight against glioblastoma.

Dianosic SAS, founded in 2017 and based in Strasbourg, France, specializes in developing advanced medical devices for Ear, Nose, and Throat (ENT) conditions. The company has created CAVI-T, an innovative intranasal balloon designed to stop spontaneous or postoperative bleeding through low-pressure compression, while also preventing biofilm formation and enhancing healing. Additionally, Dianosic is working on the Active Resorbable Intranasal Scaffold (ARIS), a groundbreaking treatment for chronic sinusitis and allergic rhinitis, which offers a long-lasting drug-eluting solution that can last from six to twelve months. This technology not only addresses patient compliance challenges but also presents opportunities for expanding treatment options in related areas such as chronic migraine and facial pain. Through its cutting-edge solutions, Dianosic aims to redefine standards of care in ENT healthcare.

Orthopus manufactures and distributes medical devices. They develop a range of robotic devices for arm mobility. Their supporter compensates for the weight of the arm to facilitate vertical movements. Their robotic device is used in an electric wheelchair and on a table.

Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

Clarity is a clinical-stage company pioneering a new category of non-pharmacological treatments for neurodegenerative diseases. We develop a neuromodulation device combining immersive technology, AI and biosensors to deliver gamma sensory stimulation. Gamma waves’ sensory stimulation has been shown to significantly slow down Alzheimer's progression, reducing neurodegeneration and cognitive decline. Clarity takes a platform approach by enabling the customization of sensory stimulation protocols based on patient data, improving experience, efficacy and scalability across a wide range of indications. The company was founded by neuroscientists from UC Berkeley, and Oxford along with execs from OURA and Philips, and is supported by leading institutions such as UCSF's Neuroscape.

Remedee Labs SAS is a French company founded in 2016, specializing in the research and development of a personal endorphin stimulator aimed at pain management. The company has created the Microelectronic Endorphin Trigger (MEET), a device designed to stimulate the release of the body’s own endorphins on demand. This innovative technology is particularly focused on helping individuals suffering from chronic pain conditions, with an initial emphasis on fibromyalgia. Remedee Labs has developed a patient-centered digital service platform that collaborates with medical practitioners to enhance chronic pain management. Backed by a decade of pre-clinical and clinical research, the company aims to provide a new approach to pain relief for the 1.5 billion people worldwide affected by chronic pain, many of whom are dissatisfied with existing treatment options. In 2019, Remedee Labs secured significant funding from various investors to further its mission of making endorphin-stimulation therapy accessible and effective for personal healthcare.

Meccellis Biotech SAS, founded in 2013 and based in La Rochelle, France, specializes in developing biologic implants using acellular dermis. The company focuses on tissue and cell engineering to create biological implants that facilitate tissue repair across various surgical specialties. Their product offerings include Cellis and Cellis breast implants, designed to address specific clinical needs during surgical procedures, such as abdominal wall repair. By maintaining continuous communication with surgeons, Meccellis Biotech aims to provide tailored solutions that meet the evolving demands of the medical field.

Guerbet is a healthcare company focused on medical imaging, with a history spanning 90 years. As a pioneer in contrast media, it is the only pharmaceutical group dedicated exclusively to this field. Guerbet operates in nearly 80 countries through a network of subsidiaries and distributors, providing a wide array of products for various imaging modalities, including CT scans, magnetic resonance imaging (MRI), ultrasound, and nuclear medicine. The company’s portfolio includes well-known brands such as Xenetix, Optiray, Dotarem, and Telebrix, among others. Additionally, Guerbet offers injectors and related medical devices aimed at enhancing patient diagnosis, prognosis, and overall quality of life.

Incepto Medical SAS, established in 2018 and headquartered in Paris, France, specializes in developing and distributing artificial intelligence (AI) applications for medical imaging. The company's portfolio includes software solutions like Qure.ai qER for head CT analysis, Qure.ai qXR for thorax abnormality detection, Aidence Veye Chest for pulmonary nodule tracking, Icometric Icobrain for neurological disorder monitoring, and ScreenPoint Transpara for breast cancer detection. Additionally, Incepto operates Collective Minds Radiology, an online platform facilitating case support, opinion sharing, and learning among healthcare professionals. The company aims to empower healthcare professionals by providing AI-driven tools that help manage the increasing volume of patients and images, ultimately enhancing patient care.

Chipiron is a developer of innovative portable MRI machines that utilize advanced quantum detectors to generate three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and efficient, significantly reducing costs compared to traditional MRI technologies. The company's focus on employing quantum sensors enhances the capability of these portable devices for disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions. This approach aims to empower healthcare institutions to improve patient outcomes and decrease the fatality rates associated with neurological diseases.

Qairn specializes in digitizing regulatory processes for healthcare manufacturers, including laboratories, medical devices, and biotechs. The company offers a SaaS platform that streamlines and secures mandatory procedures, facilitating the management of promotional materials and other regulated content. Qairn's services include the review and validation of promotional documents, submission to ANSM, and compliance support, allowing clients to efficiently navigate regulatory requirements while minimizing risks. By simplifying these processes, Qairn enables its clients to focus on innovation and improving healthcare outcomes.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Nurea develops a decision-making support solution specifically for healthcare professionals, particularly vascular surgeons. The company specializes in medical imaging software that automates image analysis, providing accurate quantitative assessments to aid in the diagnosis of vascular diseases. Its platform facilitates the management of patient groups during both pre- and post-operative monitoring through an automated workflow, which includes comprehensive full-body scan analysis. By offering decision indicators aimed at preventing cardiovascular incidents, Nurea simplifies the decision-making process for surgeons, enhancing patient care in the realm of cardiovascular health. An online inquiry form is available on their website for further information.

Healshape is a biotech startup dedicated to developing natural breast reconstruction solutions for women. The company specializes in regenerative medicine, focusing on creating innovative alternatives for breast regeneration through advanced 3D bioprinting technology. Healshape's primary product is a bioprosthesis designed for breast reconstruction, which aims to empower women by helping them regain self-confidence and achieve long-lasting, aesthetically pleasing results following surgery.

Intradys is a developer of medical software technologies focused on interventional neuroradiology. The company creates algorithms that leverage machine learning and mixed reality to assist practitioners in formulating optimal strategies based on various criteria, including patient age, medical history, and the suitability of devices for specific conditions. By utilizing imaging obtained before or during procedures, Intradys enables neuroradiologists to make informed decisions in real-time during surgeries, thereby enhancing the overall effectiveness of interventional treatments.

Diabeloop is a medical device company based in Grenoble, France, focused on innovating diabetes treatment through advanced technology. Founded in 2015, the company specializes in developing an AI-based closed-loop system that automates insulin delivery for individuals with type 1 diabetes. This system includes a blood sugar monitoring device that combines a glucose sensor, an insulin pump, and a smartphone application featuring an embedded algorithm. By continuously measuring glucose levels and delivering the appropriate insulin dosage, Diabeloop aims to reduce the mental burden on patients, allowing them to manage their condition more effectively and live their lives with greater ease.

Hemerion is a biotechnology company dedicated to developing innovative cancer treatments, specifically targeting glioblastoma, the most prevalent and aggressive primary brain tumor. The company operates a platform that integrates therapeutic services at the intersection of surgery and photonics, utilizing a photosensitizing drug for a drug-device combination therapy. This approach enables healthcare professionals to selectively destroy cancer cells in regions that are difficult to access through traditional surgical methods, all while preserving healthy tissues. Hemerion's focus on advanced treatment options aims to enhance the healthcare industry's ability to combat brain cancer and improve patient outcomes in the fight against glioblastoma.

LimFlow is a developer of innovative peripheral endovascular technology aimed at treating end-stage chronic limb ischemia (CLI) patients. The LimFlow System uses a novel, ultrasound-guided percutaneous procedure to divert blood around diseased arteries into the tibial vein, effectively supplying oxygenated blood to the ischemic foot. This approach offers new hope to patients who have exhausted other revascularization options. By restoring blood flow, the system alleviates ischemic pain, promotes wound healing, reduces the risk of amputations, and helps restore mobility. Currently, the LimFlow System is approved for sale in markets regulated by the CE Mark, while in the United States, it remains an investigational device limited to research use.

Guard Medical is a medical device company that specializes in developing innovative solutions for wound care. Its primary product, NPseal™, is designed for prophylactic negative pressure wound therapy (NPWT) of closed surgical incisions. This device aims to reduce surgical site infections and improve the healing process by establishing and maintaining negative pressure with minimal effort. By integrating an easy-to-use pump, NPseal™ allows patients to effectively prevent infection and minimize scarring, ultimately enhancing the cosmetic outcomes of surgical wounds. The company focuses on creating cost-effective alternatives that prioritize patient care and recovery.

Cairdac is a medtech startup focused on developing an innovative leadless pacing system that utilizes a self-sustaining power technology. The company has achieved a significant milestone by creating the first self-sustaining pacemaker with a lifespan exceeding 15 years, leveraging a proprietary piezoelectric energy harvester in conjunction with a miniaturized power management circuit. Their unique product, the ALPS, is an autonomous and endoscopically implanted leadless pacemaker designed to harness the heart's kinetic energy for power. By integrating disruptive technologies into traditional pacemaker designs, Cairdac aims to provide a cost-effective solution that addresses the evolving needs of patients and healthcare professionals while enhancing the overall quality of life for those requiring cardiac rhythm management.

VistaCare is a French company specializing in the development, manufacturing, and distribution of medical devices designed for the treatment of acute and chronic wounds. The company focuses on innovative, non-contact treatment methods that operate in a controlled environment. Their technology addresses critical aspects of wound care, including the reduction of nosocomial risks, visual monitoring of wound progression, and tailored medical protocols based on the specific type and stage of each wound. By enhancing the quality of life for patients and streamlining the care process for caregivers, VistaCare aims to significantly reduce treatment times and hospital stays, offering a more effective solution for complex wounds that are challenging to manage with conventional therapies.

Wandercraft specializes in the development and sale of advanced exoskeletons that enable individuals with mobility impairments to walk independently. Its flagship product, Atalante, is the first exoskeleton designed for self-balanced walking, providing a realistic gait without the need for crutches or other aids. Since receiving CE-mark approval in 2019, Atalante has been utilized in European rehabilitation hospitals to assist with gait re-learning therapies. The company is also pursuing FDA approval for its technology. Additionally, Wandercraft is working on a more compact and agile Personal Mobility exoskeleton intended for everyday use. By integrating expertise in algorithmics, artificial intelligence, robotics, and clinical applications, Wandercraft aims to create innovative solutions that enhance the autonomy and quality of life for individuals with mobility challenges.

SPARTHA Medical is a medical technology company focused on developing innovative coatings that enhance the safety of medical devices and consumer products by protecting against microbial and inflammatory risks. The company utilizes natural biopolymers to create invisible, eco-friendly, and biocompatible coatings that possess antibacterial, antiviral, and anti-inflammatory properties. By employing a patented technology that allows for the precise control of the assembly of two different polyelectrolytes, SPARTHA Medical's products can be tailored to meet diverse requirements across various fields. These multifunctional and easy-to-apply coating solutions aim to help healthcare institutions maintain disease-free surfaces on medical devices, thereby enhancing patient safety and reducing infection risks.

Quantum Surgical is a company focused on enhancing the treatment of liver cancer through minimally invasive procedures. They develop surgical robotics that provide intelligent tools for advanced percutaneous ablation therapy, which is designed to improve patient outcomes and safety in interventional oncology. By democratizing access to these innovative treatment options, Quantum Surgical aims to enable healthcare providers to more effectively cure patients and enhance their quality of life.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

Omini is a French company, established in 2019 and based in Saint Mandé, that specializes in the development of portable and multipurpose bio-sensing devices for blood testing. The company’s biosensor platform allows for the simultaneous detection of multiple biomarkers, providing personalized blood biomarker data that can be utilized to tailor therapies and prevent acute crises in patients with chronic conditions. By employing advanced multiplex electrochemical biosensor technology, Omini's devices offer accurate and affordable solutions for identifying, analyzing, and monitoring various target biomarkers. This innovation supports decentralized testing and at-home monitoring, ultimately aiming to alleviate the burden on healthcare systems and improve patient outcomes. Omini primarily serves general practitioners, enhancing their ability to manage patient care effectively.

Grapheal is a Medtech startup focused on developing embedded and wearable biosensors that leverage graphene transistors for enhanced functionality. Their devices are designed to be minimalistic and digital, enabling the dosing of biomarkers and detection of pathogens through a smartphone interface. By integrating advanced sensing nanomaterials with wireless connectivity and data analysis capabilities, Grapheal's biosensors facilitate field diagnostics and remote patient monitoring. This approach aims to make healthcare more accessible and accurate, allowing medical professionals to effectively monitor patient progress and healing.

eCential Robotics specializes in enhancing minimally invasive surgical procedures through advanced imaging technology. The company has developed a system that combines fluoroscopy, surgical navigation, and robotics to improve treatment outcomes across various medical indications. This integrated operating system offers high-definition imaging and real-time navigation, which aids surgeons in performing complex orthopedic and trauma surgeries. By enabling day surgery practices, eCential Robotics provides significant benefits to patients and healthcare providers alike, including reduced radiation exposure, increased safety, and improved accuracy during operations.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

In&motion is a company that specializes in developing wearable smart protection systems aimed at reducing the risk of serious injuries from falls. The company has created a smart ski airbag vest equipped with advanced sensors and algorithms that monitor a skier's movements in real time. This technology allows the vest to anticipate falls and activate the airbag bladder before impact, providing optimal protection for both broad and critical areas of the body. The smart ski airbag vest has received multiple awards and was used by competitors in the 2015-16 Ski Cross World Cup, representing seven major countries. As of September, the vest became available for purchase through a partnership with the Swedish brand POC, making it accessible to a wider audience of athletes and skiing enthusiasts who prioritize safety.

Lucine is focused on transforming patient health, primarily in the area of pain management. The company has developed a mobile health application that measures, analyzes, and alleviates pain from the comfort of home. Utilizing advanced algorithms, the application identifies the nature of a patient's pain by analyzing facial expressions, vocal cues, and posture. Based on this real-time assessment, it personalizes treatment options, offering techniques such as exercises, relaxation methods, art therapy, and meditation. The application aims to provide relief within five minutes through innovative analgesic neurostimulation, empowering patients with chronic pain to manage their symptoms effectively.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Multiwave Imaging is a leading company specializing in the design of metamaterial antennas for Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) systems. Established in March 2015 and headquartered in Geneva, Switzerland, with a research and development facility in France, Multiwave focuses on developing innovative medical imaging devices. The company aims to enhance imaging quality in MRI, ultimately aiding in the treatment of neurological conditions. In addition to its core imaging technologies, Multiwave employs advanced quantitative portfolio analysis and sensor technologies to support retailers in their purchasing strategies, thereby maximizing profits. Through these initiatives, Multiwave Imaging seeks to advance the field of medical imaging while addressing critical healthcare needs.

Moon Surgical is a medical device company focused on enhancing laparoscopic surgery through its innovative Maestro System. This system is designed to facilitate access to minimally invasive surgical techniques while optimizing resource utilization in the operating room. By providing features such as stabilization and automatic positioning of endoscopes, along with organ retraction, the Maestro System aims to improve surgical efficiency and patient care. Moon Surgical's technology allows surgeons to maintain their existing workflows and techniques, integrating the advantages of robotic assistance without disrupting traditional practices. Through its commitment to advancing surgical technology, Moon Surgical seeks to transform the landscape of surgery today.

Quantum Surgical is a company focused on enhancing the treatment of liver cancer through minimally invasive procedures. They develop surgical robotics that provide intelligent tools for advanced percutaneous ablation therapy, which is designed to improve patient outcomes and safety in interventional oncology. By democratizing access to these innovative treatment options, Quantum Surgical aims to enable healthcare providers to more effectively cure patients and enhance their quality of life.

Ambler is a startup founded in 2018 by experts in digital and so-called "marketplace" models 100% French, the company enjoys the support of public authorities (Wilco-ex Scientipôle) and the support of prestigious private investors , including Partech, Idinvest Partners, Kima Ventures. The startup is developing technologies to help match the supply and demand of medical transports. It aggregates, thanks to win-win partnerships, a considerable fleet of vehicles and offers unparalleled deliverability for contractors. Ambler is the only solution capable, nationwide, of absorbing the constant growth of health transport flows induced by demographic and regulatory factors (reform of regional hospital groups).

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

Dianosic SAS, founded in 2017 and based in Strasbourg, France, specializes in developing advanced medical devices for Ear, Nose, and Throat (ENT) conditions. The company has created CAVI-T, an innovative intranasal balloon designed to stop spontaneous or postoperative bleeding through low-pressure compression, while also preventing biofilm formation and enhancing healing. Additionally, Dianosic is working on the Active Resorbable Intranasal Scaffold (ARIS), a groundbreaking treatment for chronic sinusitis and allergic rhinitis, which offers a long-lasting drug-eluting solution that can last from six to twelve months. This technology not only addresses patient compliance challenges but also presents opportunities for expanding treatment options in related areas such as chronic migraine and facial pain. Through its cutting-edge solutions, Dianosic aims to redefine standards of care in ENT healthcare.

Multiwave Imaging is a leading company specializing in the design of metamaterial antennas for Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) systems. Established in March 2015 and headquartered in Geneva, Switzerland, with a research and development facility in France, Multiwave focuses on developing innovative medical imaging devices. The company aims to enhance imaging quality in MRI, ultimately aiding in the treatment of neurological conditions. In addition to its core imaging technologies, Multiwave employs advanced quantitative portfolio analysis and sensor technologies to support retailers in their purchasing strategies, thereby maximizing profits. Through these initiatives, Multiwave Imaging seeks to advance the field of medical imaging while addressing critical healthcare needs.

Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, that specializes in the design, development, and production of amorphous metal parts. Founded in 2017, Vulkam utilizes biocompatible amorphous metal alloys primarily composed of materials such as zirconium, copper, hafnium, nickel, and titanium. The company's innovative products find applications across various industries, including aerospace, automotive, biomedical, cryogenic, watches, jewellery, and micro components. Vulkam's focus on creating micromechanical parts that are significantly smaller yet maintain strength and functionality sets a new standard in metallurgy and metal processing, positioning the company as a leader in the development of advanced metal technologies.

Laclarée Vision specializes in the development of adaptive eyeglasses designed to correct presbyopia. Founded in 2016 and based in Lyon, France, the company utilizes patented fluid technology to create lenses that automatically adjust in real-time to various viewing distances. This innovative approach addresses the needs of individuals aged 45 and older who often find traditional solutions, such as progressive lenses or multiple pairs of glasses, unsatisfactory. By combining adaptive lens technology with refractive correction for conditions like astigmatism, myopia, and hyperopia, Laclarée aims to provide a clearer vision experience for its users.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through innovative, digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling continuous remote monitoring of patients' health data, BioSerenity aims to optimize patient pathways in cardiology, neurology, and sleep disorders. The company also collaborates with the scientific community by providing anonymized data to researchers at the Institut du Cerveau et de la Moelle épinière (ICM), thereby contributing to advancements in epilepsy research and improving future diagnostic methods.

Volta Medical is a technology company based in Marseille, France, founded in 2016, that specializes in developing artificial intelligence software for interventional cardiology. The company focuses on aiding cardiologists in the treatment of atrial fibrillation, the most common cardiac arrhythmia. Volta Medical's flagship product utilizes advanced AI algorithms to analyze electrograms and guide mapping catheters during cardiac procedures. This software assists interventional cardiologists by providing real-time insights and step-by-step guidance, enhancing their ability to make informed decisions during patient-specific medical interventions. The company aims to improve the effectiveness of cardiac procedures and the overall management of atrial fibrillation through innovative technological solutions.

ADDEV Materials SAS, founded in 2006 and based in Lyon, France, specializes in the manufacturing and distribution of high-performance materials, including adhesive tapes, glues, mastics, abrasives, insulation, and technical components. The company serves a variety of industries, such as automotive, aerospace, energy, railway, nuclear, and medical, by transforming and custom cutting various types of insulation and technical films. Additionally, ADDEV Materials provides customized solutions and distribution services for technical adhesives, helping clients address their specific technical challenges effectively.

Neurallys is a Paris-based company specializing in the development and production of medical devices for neurology and neurosurgery. The company has created an intelligent sensor that communicates with a smartphone to monitor intracranial pressure in patients with hydrocephalus. This innovative device aims to enhance patient comfort and provide neurosurgeons with a valuable tool for more effective management and follow-up of the condition, ultimately improving the quality of care for those affected by hydrocephalus.

Igyxos S.A. is a French company based in Nouzilly that focuses on developing pharmaceuticals and medical technologies aimed at enhancing human fertility. Established in 2017, Igyxos engages in all stages of drug development, beginning with the discovery of promising targets and progressing to the identification of lead compounds, including small molecules and monoclonal antibodies. The company specializes in developing solutions that improve the efficacy of gonadotropins and hormones critical for reproduction. Igyxos also facilitates the transition of potential drug candidates through pre-clinical and clinical phases, aiming to address the increasing global demand for effective infertility treatments for both men and women.

SuperSonic Imagine SA is a medical technology company that specializes in developing and manufacturing advanced ultrasound imaging systems. Founded in 2005 and headquartered in Aix-en-Provence, France, the company is renowned for its Aixplorer system, which provides high-definition imaging and is particularly effective in diagnosing and monitoring breast, prostate, and thyroid cancers, as well as liver diseases. The Aixplorer system incorporates ShearWave technology, enabling quantitative elastography that measures tissue elasticity. SuperSonic Imagine operates primarily in markets such as China, the United States, and various European countries, distributing its products through a network of offices and distributors. As a subsidiary of Hologic Hub Ltd, the company continues to innovate in the field of medical imaging, enhancing the capabilities of healthcare professionals.

Presto Engineering, Inc. is a provider of outsourced development operations tailored for semiconductor and Internet of Things (IoT) device companies. Established in 2006 and headquartered in San Jose, California, the company delivers a comprehensive suite of services, including turnkey IoT components, radio-frequency (RF) and mixed-signal solutions, and various testing and analysis services. These services encompass product engineering, debugging, reliability testing, and failure analysis, aimed at enhancing product performance and minimizing risk. Presto Engineering also specializes in wafer fabrication, backend packaging, and supply chain solutions, supporting clients in the medical, automotive, industrial, and communication sectors. With additional offices in France, Thailand, and Taiwan, the company is positioned to facilitate rapid product development and help clients accelerate their time-to-market.

C4Diagnostics specializes in the development and commercialization of in vitro diagnostic (IVD) kits utilizing its proprietary technology. The company focuses on creating medical devices and equipment that enhance the speed and sensitivity of diagnostic tests. One of its primary offerings includes solutions for urinary tract infection screening, which reliably detects, counts, and concentrates culturable microorganisms relevant to clinical microbiology. This capability allows hospitals and laboratories to conduct culture-based IVD tests with improved accuracy and efficiency, contributing to better patient outcomes in diagnostic processes.

Dreem is a neurotechnology company focused on enhancing human potential through innovative consumer technology. Its primary product is a wearable device that improves the quality of deep sleep by monitoring brainwaves and analyzing sleep patterns. The device employs sound stimulation to extend deep sleep duration, which can lead to improved daily performance. By utilizing machine learning algorithms, Dreem's headband provides real-time analysis of sleep stages and delivers personalized insights and tips that adapt based on individual sleeping habits. This approach aims to help users achieve faster sleep onset, longer deep sleep, and a refreshed awakening.

LimFlow is a developer of innovative peripheral endovascular technology aimed at treating end-stage chronic limb ischemia (CLI) patients. The LimFlow System uses a novel, ultrasound-guided percutaneous procedure to divert blood around diseased arteries into the tibial vein, effectively supplying oxygenated blood to the ischemic foot. This approach offers new hope to patients who have exhausted other revascularization options. By restoring blood flow, the system alleviates ischemic pain, promotes wound healing, reduces the risk of amputations, and helps restore mobility. Currently, the LimFlow System is approved for sale in markets regulated by the CE Mark, while in the United States, it remains an investigational device limited to research use.

eCential Robotics specializes in enhancing minimally invasive surgical procedures through advanced imaging technology. The company has developed a system that combines fluoroscopy, surgical navigation, and robotics to improve treatment outcomes across various medical indications. This integrated operating system offers high-definition imaging and real-time navigation, which aids surgeons in performing complex orthopedic and trauma surgeries. By enabling day surgery practices, eCential Robotics provides significant benefits to patients and healthcare providers alike, including reduced radiation exposure, increased safety, and improved accuracy during operations.

Fizimed SAS, founded in 2017 and based in Strasbourg, France, specializes in manufacturing a perineal device designed to address urinary incontinence in women through pelvic floor reeducation. The company's flagship product, EMY, is a perineal probe that connects to a mobile app, allowing users to engage in personalized exercises for strengthening pelvic floor muscles. EMY not only captures real-time muscle contractions but also incorporates interactive elements, such as games, to motivate users during their five-minute workouts. Fizimed emphasizes user-friendliness and safety in its product design, aiming to empower women in managing their pelvic health at home. Additionally, the company actively seeks to eliminate the stigma surrounding urinary incontinence, fostering a supportive community on social media where women can share experiences and innovations related to this common health issue. Through its combination of medical efficacy and engaging technology, Fizimed aims to provide women with the tools they need to regain control over their pelvic health in a discreet and enjoyable manner.

Belovia designs, manufactures, and markets medical devices aimed at assisting patients and caregivers in post-surgical settings. The company's product range includes electronic stocking donners, light solutions for physical mobilization, and mechatronic stocking donners tailored for use by medical professionals. By focusing on physical mobilization assistance, Belovia seeks to enhance patient dignity and support caregivers in their roles, ultimately improving the overall experience in hospital departments.

Wandercraft specializes in the development and sale of advanced exoskeletons that enable individuals with mobility impairments to walk independently. Its flagship product, Atalante, is the first exoskeleton designed for self-balanced walking, providing a realistic gait without the need for crutches or other aids. Since receiving CE-mark approval in 2019, Atalante has been utilized in European rehabilitation hospitals to assist with gait re-learning therapies. The company is also pursuing FDA approval for its technology. Additionally, Wandercraft is working on a more compact and agile Personal Mobility exoskeleton intended for everyday use. By integrating expertise in algorithmics, artificial intelligence, robotics, and clinical applications, Wandercraft aims to create innovative solutions that enhance the autonomy and quality of life for individuals with mobility challenges.

BioSerenity is a company focused on enhancing the understanding and treatment of epilepsy and other chronic diseases through innovative, digitally connected devices. These devices facilitate the retrieval and interpretation of electrophysiological signals, including electroencephalograms, electrocardiograms, and polysomnography. By enabling continuous remote monitoring of patients' health data, BioSerenity aims to optimize patient pathways in cardiology, neurology, and sleep disorders. The company also collaborates with the scientific community by providing anonymized data to researchers at the Institut du Cerveau et de la Moelle épinière (ICM), thereby contributing to advancements in epilepsy research and improving future diagnostic methods.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

Conscious Labs specializes in developing brain-computer interface (BCI) technology that allows for the collection of research-grade EEG data in real-world settings. The company creates advanced head-wearable devices designed to integrate seamlessly into headphones, earbuds, and VR and AR headsets. This technology enables electronics manufacturers and startups to embed BCI capabilities into their products, facilitating out-of-lab research and enhancing user experiences. Additionally, Conscious Labs offers expertise in sensor development and provides an innovative ionic polymer suitable for biosensors in wearable devices, thereby advancing the capabilities of biosensing technologies.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

SpineGuard is a French medical company focused on the design and production of innovative instruments for spinal surgeries, utilizing its proprietary Dynamic Surgical Guidance (DSG®) technology. This powerful, radiation-free sensing platform enhances the accuracy and safety of skeletal implant placement through real-time audio and visual feedback for surgeons. The company's flagship product, the PediGuard probe, is specifically designed for spine surgery, allowing surgeons to create pilot holes in vertebrae with precision. Equipped with a sensor that measures electrical conductivity, the PediGuard alerts surgeons to changes in bone and tissue types without the need for X-ray imaging. Available in various shapes and sizes, these devices cater to a wide range of surgical needs, from pediatric deformity corrections to adult degenerative conditions. With over 80,000 successful spinal procedures supported by PediGuard and substantial clinical evidence backing its efficacy, SpineGuard aims to address critical challenges in pedicle screw placement while improving patient outcomes and operational efficiency in the surgical environment.

Biom'Up S.A. is a French company based in Saint-Priest that specializes in the development and commercialization of hemostatic products utilizing patented biopolymers and collagen technology. Established in 2005, Biom'Up designs, manufactures, and sells innovative medical devices that enhance surgical practices across various specialties, including orthopedic, spinal, cardiac, general, maxillofacial, and laparoscopic surgeries. Their flagship products, HEMOBLAST bellows and associated laparoscopic applicators, aim to simplify surgical procedures and improve patient outcomes by facilitating guided regeneration of soft tissues and bone. The company markets its offerings primarily in Europe and the United States.

Lewis Industries specializes in the design and manufacture of precision sheet metal parts, incorporating electronic components as necessary to deliver fully assembled equipment. Founded in 1966 and based in Nemours, France, the company serves various sectors including medical, lighting, information technology, telecommunications, heating, transport, and instrumentation. With over 40 years of experience, Lewis Industries is known for its expertise in high precision operations such as laser cutting, sheet metal bending, welding, assembly, and finishing. The company is committed to providing parts with both simple and complex geometries, as well as functional units tailored to the specific needs of its clients.

Theravectys is a biotechnology company focused on developing a novel vaccine platform aimed at treating and preventing a wide array of infectious diseases, cancers, and other medical conditions. The company’s innovative vaccination technology utilizes gene transfer into dendritic cells to modulate the immune response, enhancing the effectiveness of both prophylactic and therapeutic immunotherapies. Their lead product, a therapeutic vaccine targeting HIV/AIDS, has demonstrated promising efficacy and safety in non-human primate studies and is set to enter clinical trials. Through its diverse pipeline, Theravectys aims to provide healthcare providers with advanced treatment options that elicit a potent and targeted immune response in patients.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

ECM Technologies SA, founded in 1928 and based in Grenoble, France, specializes in the design and manufacture of industrial heat treating solutions. The company produces a wide range of furnaces, including vacuum, induction, and carburizing furnaces, as well as photovoltaic and crystal growth equipment. ECM Technologies serves various sectors, such as aeronautics, automotive, nuclear, healthcare, and electronics, providing essential equipment for processes like low pressure carburizing, brazing, and melting. In addition to manufacturing, the company offers retrofit and after-sale support services, including the sale of used furnaces. Its products are marketed globally through agents, distributors, and subsidiaries located in several countries, including the United States, Germany, China, and India.

Santen is a pharmaceutical company specializing in ophthalmic products, dedicated to improving the quality of life for patients worldwide. With over 120 years of research experience, Santen focuses primarily on the development of prescription ophthalmic pharmaceuticals, which constitutes the majority of its revenue. The company also offers over-the-counter medications and medical devices under its other operating segment. Santen's clinical development network spans Europe, Japan, and the United States, reflecting its commitment to addressing unmet needs in ophthalmology through innovative therapies and collaborative efforts. Most of its sales are generated in Japan, with a growing presence in other Asian markets.

Santen is a pharmaceutical company specializing in ophthalmic products, dedicated to improving the quality of life for patients worldwide. With over 120 years of research experience, Santen focuses primarily on the development of prescription ophthalmic pharmaceuticals, which constitutes the majority of its revenue. The company also offers over-the-counter medications and medical devices under its other operating segment. Santen's clinical development network spans Europe, Japan, and the United States, reflecting its commitment to addressing unmet needs in ophthalmology through innovative therapies and collaborative efforts. Most of its sales are generated in Japan, with a growing presence in other Asian markets.

Santen is a pharmaceutical company specializing in ophthalmic products, dedicated to improving the quality of life for patients worldwide. With over 120 years of research experience, Santen focuses primarily on the development of prescription ophthalmic pharmaceuticals, which constitutes the majority of its revenue. The company also offers over-the-counter medications and medical devices under its other operating segment. Santen's clinical development network spans Europe, Japan, and the United States, reflecting its commitment to addressing unmet needs in ophthalmology through innovative therapies and collaborative efforts. Most of its sales are generated in Japan, with a growing presence in other Asian markets.

Santen is a pharmaceutical company specializing in ophthalmic products, dedicated to improving the quality of life for patients worldwide. With over 120 years of research experience, Santen focuses primarily on the development of prescription ophthalmic pharmaceuticals, which constitutes the majority of its revenue. The company also offers over-the-counter medications and medical devices under its other operating segment. Santen's clinical development network spans Europe, Japan, and the United States, reflecting its commitment to addressing unmet needs in ophthalmology through innovative therapies and collaborative efforts. Most of its sales are generated in Japan, with a growing presence in other Asian markets.

Oxxius SA specializes in the development, design, manufacturing, and sale of diode-pumped solid-state lasers and laser diode modules. Founded in 2002 and headquartered in Lannion, France, the company produces a range of lasers including UV, visible, and infrared options, as well as ultra-stable and single longitudinal mode laser modules. These products serve various applications such as fluorescence analysis in flow cytometry and microscopy, interferometry in laser Doppler velocimetry and holography, and Raman spectroscopy. Oxxius's innovative laser technology offers significant advancements in compactness, reliability, and cost-efficiency, catering to both research and industrial markets. The company distributes its products through a network of partners across multiple countries, ensuring wide accessibility for its offerings in bio-photonics, metrology, and spectroscopy.

Hemerion is a biotechnology company dedicated to developing innovative cancer treatments, specifically targeting glioblastoma, the most prevalent and aggressive primary brain tumor. The company operates a platform that integrates therapeutic services at the intersection of surgery and photonics, utilizing a photosensitizing drug for a drug-device combination therapy. This approach enables healthcare professionals to selectively destroy cancer cells in regions that are difficult to access through traditional surgical methods, all while preserving healthy tissues. Hemerion's focus on advanced treatment options aims to enhance the healthcare industry's ability to combat brain cancer and improve patient outcomes in the fight against glioblastoma.